Equities research analysts predict that Cancer Genetics, Inc. (NASDAQ:CGIX) will post sales of $9.45 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cancer Genetics’ earnings, with the highest sales estimate coming in at $9.90 million and the lowest estimate coming in at $9.00 million. Cancer Genetics posted sales of $7.23 million during the same quarter last year, which would indicate a positive year over year growth rate of 30.7%. The firm is expected to report its next quarterly earnings report on Thursday, March 22nd.
On average, analysts expect that Cancer Genetics will report full year sales of $9.45 million for the current fiscal year, with estimates ranging from $30.17 million to $31.79 million. For the next year, analysts forecast that the firm will post sales of $43.10 million per share, with estimates ranging from $37.70 million to $48.49 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Cancer Genetics.
Several brokerages have commented on CGIX. HC Wainwright set a $6.00 price target on shares of Cancer Genetics and gave the company a “buy” rating in a research report on Tuesday, August 15th. Zacks Investment Research cut shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, ValuEngine cut shares of Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $5.42.
Cancer Genetics (NASDAQ CGIX) opened at $2.70 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a 1 year low of $1.30 and a 1 year high of $5.30.
Institutional investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. purchased a new stake in shares of Cancer Genetics during the 1st quarter worth $102,000. Northern Trust Corp lifted its position in shares of Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after purchasing an additional 12,168 shares during the last quarter. Thompson Davis & CO. Inc. lifted its position in shares of Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after purchasing an additional 109,300 shares during the last quarter. Granahan Investment Management Inc. MA lifted its position in shares of Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after purchasing an additional 49,371 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after purchasing an additional 139,200 shares during the last quarter. 12.27% of the stock is owned by institutional investors and hedge funds.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.